BFRI Share Price Performance
US$0
-0.66 (-100.00%)
Price US$0
Fair ValueUS$3.00
Share Pricen/a
Biofrontera Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
BFRI Community Narratives
AN
Fair Value
·Fair Value US$3 66.7% undervalued intrinsic discount
Regulatory And Litigation Risks Will Constrain Growth But Enable Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$6.5 84.6% undervalued intrinsic discount
Label Expansion And New Trials Will Fuel US Dermatology Demand
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value
·Fair Value US$10 90.0% undervalued intrinsic discount
Ameluz Expansion Will Harness Secular Trends In Dermatology
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regulatory And Litigation Risks Will Constrain Growth But Enable Recovery
Key Takeaways Heavy reliance on a single product and exposure to litigation and patent costs threaten earnings and margins despite operational improvements and potential for higher profitability. Growth prospects are challenged by regulatory and pricing pressures, uncertain R&D outcomes, and vulnerability to sector consolidation due to its smaller market presence.Read more
AN
US$3
66.7% undervalued intrinsic discount
Fair Value
Profit Margin
27.01%
Future PE
2.61x
Price in 2028
US$2.03
Ameluz Expansion Will Harness Secular Trends In Dermatology
Key Takeaways Full US manufacturing control, improved reimbursement, and label expansion could drive a step-change in market share, margins, and top-line growth beyond current expectations. Data-driven salesforce expansion, clinician preference shifts, and global market opportunities position the company for outsized, multi-region scaling and profit growth.Read more
AN
US$10
90.0% undervalued intrinsic discount
Fair Value
Profit Margin
27.18%
Future PE
8.61x
Price in 2028
US$12.11
Label Expansion And New Trials Will Fuel US Dermatology Demand
Key Takeaways Expansion of Ameluz indications, improved reimbursement, and patent extension are set to drive revenue growth and strengthen market position amid rising skin cancer rates. Reduced costs due to lower royalties and focus on new dermatological indications are expected to improve margins and enable future product launches.Read more
AN
US$6.5
84.6% undervalued intrinsic discount
Fair Value
Profit Margin
30.7%
Future PE
4.79x
Price in 2028
US$4.39
Trending Discussion
Recently Updated Narratives
AN
Regulatory And Litigation Risks Will Constrain Growth But Enable Recovery
Fair Value: US$3 66.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Ameluz Expansion Will Harness Secular Trends In Dermatology
Fair Value: US$10 90.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Label Expansion And New Trials Will Fuel US Dermatology Demand
Fair Value: US$6.5 84.6% undervalued intrinsic discount
8 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Biofrontera Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.92
- 77.29%
- -25.66%
- 77.7%
About BFRI
- Founded
- 2015
- Employees
- 89
- CEO
- WebsiteView website
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
